[Evolution of the number of incident cases, stage and first treatments for prostate cancer in France between 2001 and 2016]

Prog Urol. 2019 Feb;29(2):108-115. doi: 10.1016/j.purol.2018.12.005. Epub 2019 Jan 9.
[Article in French]

Abstract

Introduction: No studies of French hospital registries for prostate cancer (PCa) have been published since the 2012 USPSTF recommendations.

Material: This is a multicenter cohort study based on hospital data of prostate biopsies (PB) in 3 health centers between 2001 and 2016. The main objective is to describe the evolution of incident cases of PCa. The secondary objectives are to describe the number of cases per stage of PCa and the distribution of the first treatments.

Results: In total, 11,491 PB series diagnosed 5927 cases of PCa. The median age was 67 [61-73] years and the median PSA was 7.8 [5.5-13] ng/mL. The number of cases increased until 2006 before decreasing from 2006 to 2013 and then stabilizing from 2013 to 2016. The proportion of incident cases was: (1) for the stable metastatic stage around 8 [7-10]%, (2) for cases with PSA<10 ng/mL increasing from 46% to 75% in 2010 down to 64% in 2016, (3) for the grade 1 group decreasing from 59% to 33 % between 2011 and 2016. The proportion of active surveillance treatment for low-risk cancers increased from 5 to 60% and surgery decreased from 73 to 33%.

Conclusion: The evolution of the incident cases showed a decrease from 2006 to 2013 and a stability until 2016. The number of cases with PSA<10 ng/mL decreased since 2010 and the proportion of the options of treatment by surveillance increased strongly to the detriment of the surgery for low risks.

Level of evidence: 3.

Keywords: Cancer de prostate; Dépistage; Epidemiology; Options de traitement; Prostate neoplasms; Screening; Stade; Stage; Treatment options; Épidémiologie.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Biopsy
  • Cohort Studies
  • France / epidemiology
  • Hospitals
  • Humans
  • Incidence
  • Male
  • Mass Screening / methods*
  • Middle Aged
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy

Substances

  • Prostate-Specific Antigen